Available Until 12/31/2023

Evolving Strategies to Cover High Investment Medications

Please note: This session is NOT accredited for continuing pharmacy education (CPE) credit.

Course Description:

Novel therapies, such as gene and cell therapy, are growing in availability and meeting medical needs for previously uncurable conditions. These important and life-saving options are associated with high initial costs raising predictability, affordability, and accessibility concerns for managed care organizations. This session will discuss various perspectives on alternative payment models, financial tools, and policy initiatives that mitigate risk and improve access to these durable cures. 


Jane Barlow, MD, MPH, MBA

Chief Clinical Officer

Real Endpoints

Ronda Copher

Senior Director

Bristol-Myers-Squibb (BMS)

Mehb Khoja, FSA, MAAA

Chief Actuary

BCS Financial

Gail Ryan, PharmD

Director of Pharmaceutical Transformation


System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.